www.fdanews.com/articles/70450-eisai-to-sell-dainippon-pharm-s-epilepsy-drug-in-asia
Eisai to Sell Dainippon Pharm's Epilepsy Drug in Asia
March 29, 2005
Eisai Co. (4523.TO) said it has acquired the rights to develop, produce and market Dainippon Pharmaceutical Co.'s (4506.TO) drug for epilepsy treatment in Asia excluding Japan. Under the agreement, Eisai, Japan's fourth-largest drug maker by sales, will develop and sell the drug in China, Taiwan and 14 other countries in Asia. In the U.S. and Europe, Elan Corp. Plc (ELN) of Ireland licensed the drug, known as Zonegran, from Dainippon. Eisai acquired the drug's rights for the U.S. and European market from Elan in March 2004.